ADHD Medication Is Now Available in Candy Form in the US

As if doctors weren't already giving out ADHD medication like it's candy, now they literally can.

by Allison Tierney
May 31 2016, 4:39pm

Adzenys XR-ODT, pictured above, is a candy-flavored ADHD medication that hit the US market this month. Image via Neos Therapeutics

Adzenys XR-ODT, pictured above, is a candy-flavoured ADHD medication that hit the US market this month. Image via Neos Therapeutics

A new ADHD medication called Adzenys XR-ODT launched this month in the US. Though the amphetamine is similar to Adderall, the pill has a major difference: It comes in a fruity candy flavour. The FDA approved Adzenys in January for patients diagnosed with ADHD six years and older, and now it's available for doctors in the United States to prescribe.

We already know that Adderall is almost identical to meth, so the implications for risk of abuse and addiction are clearly already present in amphetamine-type ADHD medications. Now, thanks in part to the Dallas-based company Neos Therapeutics that launched the drug, there's the added complication of an already known dangerous substance coming in a tastier and more convenient form. Adzenys pills are round, orange, come in a blister pack, and are available in six different dosages.

The company's CEO Vipin Garg said that Adzenys hitting the market comes "ahead of back-to-school season," and that they're "launching now at full speed."

While some psychiatrists are condemning the release of Adzenys XR-ODT because it could potentially increase the risk of abusing ADHD drugs, others are saying that it's a natural progression in prescription drug development.

Though this is obviously not the first time drugs or supplements have become available in a sweet, candy-like form that is targeted to children (prime example: Flintstones and gummy vitamins), this is the first time that this particular amphetamine-type ADHD med has been made available in this iteration.

Mixing candy with medication is increasingly becoming a trend in the health industry. Earlier this month, Bloomberg Business Week explored Nestlé's foray into big pharma.

Follow Allison Tierney on Twitter.

Allison Tierney
Vice Guide to Right Now
Allison Tierney VICE
Neos Therapeutics
Vipin Garg